A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers

Adjuvant chemotherapy is considered the standard of care for patients with colorectal cancer after curative resection. Although current guidelines provide clear instructions for chemotherapy for stage II high-risk and stage III colorectal cancer, it is insufficient to individualize therapy. We analy...

Full description

Bibliographic Details
Main Authors:	Han, Yang, Lu, Su, Yu, Fudong, Liu, Xisheng, Sun, Huimin, Wang, Jingtao, Zhu, Xingwu, Lu, Huijun, Yue, Hao, Wang, Jing, Lin, Jun, Zhou, Chongzhi, Tang, Huamei, Peng, Zhihai
Format:	Online
Language:	English
Published:	Nature Publishing Group 2016
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109035/

id	pubmed-5109035
recordtype	oai_dc
spelling	pubmed-51090352016-11-25 A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers Han, Yang Lu, Su Yu, Fudong Liu, Xisheng Sun, Huimin Wang, Jingtao Zhu, Xingwu Lu, Huijun Yue, Hao Wang, Jing Lin, Jun Zhou, Chongzhi Tang, Huamei Peng, Zhihai Article Adjuvant chemotherapy is considered the standard of care for patients with colorectal cancer after curative resection. Although current guidelines provide clear instructions for chemotherapy for stage II high-risk and stage III colorectal cancer, it is insufficient to individualize therapy. We analyzed the outcomes of 902 patients with colorectal cancer treated with or without chemotherapy in our hospital. We found Chinese survival benefit for chemotherapy was consistent with current guidelines. Moreover, our data added to the evidence that chemotherapy might be used for elderly patients with stage II high-risk colorectal cancer. Pathological markers could predict response to individualize therapy in a convenient, fast and inexpensive way. We compared survivals of patients with stage II high-risk and stage III colorectal cancer with chemotherapy in different pathological markers expression, and furthermore used 458 colon adenocarcinoma samples from The Cancer Genome Atlas to verify our preliminary results. We confirmed TOPIIα, EGFR and P170 may be sufficiently predictive markers to individualize chemotherapy. FOLFOX was the optimal adjuvant chemotherapy for patients with stage II high-risk and stage III colorectal cancer when TOPIIα was positive or EGFR or P170 was negative. Nature Publishing Group 2016-11-15 /pmc/articles/PMC5109035/ /pubmed/27845412 http://dx.doi.org/10.1038/srep37240 Text en Copyright © 2016, The Author(s) http://creativecommons.org/licenses/by/4.0/ This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
repository_type	Open Access Journal
institution_category	Foreign Institution
institution	US National Center for Biotechnology Information
building	NCBI PubMed
collection	Online Access
language	English
format	Online
author	Han, Yang Lu, Su Yu, Fudong Liu, Xisheng Sun, Huimin Wang, Jingtao Zhu, Xingwu Lu, Huijun Yue, Hao Wang, Jing Lin, Jun Zhou, Chongzhi Tang, Huamei Peng, Zhihai
spellingShingle	Han, Yang Lu, Su Yu, Fudong Liu, Xisheng Sun, Huimin Wang, Jingtao Zhu, Xingwu Lu, Huijun Yue, Hao Wang, Jing Lin, Jun Zhou, Chongzhi Tang, Huamei Peng, Zhihai A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers
author_facet	Han, Yang Lu, Su Yu, Fudong Liu, Xisheng Sun, Huimin Wang, Jingtao Zhu, Xingwu Lu, Huijun Yue, Hao Wang, Jing Lin, Jun Zhou, Chongzhi Tang, Huamei Peng, Zhihai
author_sort	Han, Yang
title	A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers
title_short	A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers
title_full	A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers
title_fullStr	A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers
title_full_unstemmed	A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers
title_sort	comparative analysis and guidance for individualized chemotherapy of stage ii and iii colorectal cancer patients based on pathological markers
description	Adjuvant chemotherapy is considered the standard of care for patients with colorectal cancer after curative resection. Although current guidelines provide clear instructions for chemotherapy for stage II high-risk and stage III colorectal cancer, it is insufficient to individualize therapy. We analyzed the outcomes of 902 patients with colorectal cancer treated with or without chemotherapy in our hospital. We found Chinese survival benefit for chemotherapy was consistent with current guidelines. Moreover, our data added to the evidence that chemotherapy might be used for elderly patients with stage II high-risk colorectal cancer. Pathological markers could predict response to individualize therapy in a convenient, fast and inexpensive way. We compared survivals of patients with stage II high-risk and stage III colorectal cancer with chemotherapy in different pathological markers expression, and furthermore used 458 colon adenocarcinoma samples from The Cancer Genome Atlas to verify our preliminary results. We confirmed TOPIIα, EGFR and P170 may be sufficiently predictive markers to individualize chemotherapy. FOLFOX was the optimal adjuvant chemotherapy for patients with stage II high-risk and stage III colorectal cancer when TOPIIα was positive or EGFR or P170 was negative.
publisher	Nature Publishing Group
publishDate	2016
url	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5109035/
_version_	1613726700460310528

A comparative analysis and guidance for individualized chemotherapy of stage II and III colorectal cancer patients based on pathological markers

Similar Items